Breaking Finance News

A statement released earlier today by Zacks Investment Research about Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) bumps the target price to $4.25

Yesterday Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) traded -3.46% lower at $3.60. The company’s 50-day moving average is $3.82 and its 200-day moving average is $4.27. The last stock close price is down -15.02% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 286,214 shares of the stock were exchanged, down from an average trading volume of 346,337

In a report issued 10/11/2016 Zacks Investment Research raised the stock price target of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) to $4.25 stating a potential upside of 0.18%.

Previously on 6/26/2015, Cantor Fitzgerald reported about Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) raised the target price from $46.00 to $50.00. At the time, this indicated a possible upside of 0%.

See Chart Below

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH)

Tetraphase Pharmaceuticals Inc has a 52 week low of $3.12 and a 52 week high of $12.45 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its target price, a total of 4 firms have reported on the stock. The consensus target price is $12.00 with 1 firm rating the stock a strong buy, 2 firms rating the stock a buy, 5 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH)

Tetraphase Pharmaceuticals, Inc. (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. It is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections. It has developed eravacycline using its chemistry technology. The Company's TP-271 is a fully synthetic spectrum preclinical compound that the Company developed for respiratory diseases caused by bacterial biothreat pathogens. The Company created TP-271 using its chemistry technology. In its development program for TP-271, the Company has conducted a number of in vitro, toxicology and animal studies to evaluate the efficacy of TP-271 against biothreat pathogens. It also develops TP-6076 for multidrug-resistant Gram- negative infections.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.